PMID- 34187049
OWN - NLM
STAT- MEDLINE
DCOM- 20220310
LR  - 20220311
IS  - 1665-1731 (Electronic)
IS  - 1405-9940 (Print)
IS  - 1665-1731 (Linking)
VI  - 92
IP  - 1
DP  - 2022 Jan 3
TI  - Latin American Consensus on management of residual cardiometabolic risk. A 
      consensus paper prepared by the Latin American Academy for the Study of Lipids 
      and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of 
      Cardiology (IASC), the International Atherosclerosis Society (IAS), and the 
      Pan-American College of Endothelium (PACE).
PG  - 99-112
LID - 10.24875/ACM.21000005 [doi]
AB  - BACKGROUND: Hypertension, hyperglycemia, dyslipidemia, overweight, obesity, and 
      tobacco (smoking, chewing, and vaping), together with a pro-inflammatory and 
      procoagulant state, are the main risk factors related to atherosclerotic 
      cardiovascular disease. OBJECTIVE AND METHODS: A group of experts from the 
      Americas, based on their clinical expertise in cardiology, cardiovascular 
      prevention, and cardiometabolic (CM) diseases, joined together to develop these 
      practical recommendations for the optimal evaluation and treatment of residual CM 
      risk factors in Latin America, using a modified Delphi methodology (details in 
      electronic TSI) to generate a comprehensive CM risk reduction guideline, and 
      through personalized medicine and patient-centered decision, considering the 
      cost-benefit ratio The process was well defined to avoid conflicts of interest 
      that could bias the discussion and recommendations. RESULTS: Residual risk 
      reduction should consider therapeutic options adapted to specific patient needs, 
      based on five treatment objectives: triglyceride-rich lipoproteins, inflammation, 
      impaired glucose metabolism, high blood pressure, and prothrombotic status. 
      Comprehensive control of all CM risk factors should be a priority to deal with 
      this important public health problem and prevent premature deaths. The 
      recommendations in this paper address the evidence-based treatment of CM risk and 
      are intended for clinical application in Latin American countries.
FAU - Ponte-Negretti, Carlos I
AU  - Ponte-Negretti CI
AD  - Unit of Cardiometabolic Medicine, La Floresta Medical Institute, Caracas, 
      Venezuela.
FAU - Wyss, Fernando S
AU  - Wyss FS
AD  - Services and Cardiovascular Technology of Guatemala CARDIOSOLUTIONS, Guatemala, 
      Guatemala.
FAU - Piskorz, Daniel
AU  - Piskorz D
AD  - Institute of Cardiology Sanatorio Britanico SRL Rosario, Argentina.
FAU - Santos, Raul D
AU  - Santos RD
AD  - Lipid Clinic Heart Institute (InCor) University of Sao Paulo Medical School 
      Hospital, Sao Paulo, Brazil.
FAU - Villar, Raul
AU  - Villar R
AD  - Integra Medica, La Serena, Chile.
FAU - Lorenzatti, Alberto
AU  - Lorenzatti A
AD  - Department of Cardiology, Hospital Instituto Medico DAMIC/Rusculleda Foundation 
      for Research in Medicine, Cordoba Argentina.
FAU - Lopez-Jaramillo, Patricio
AU  - Lopez-Jaramillo P
AD  - Integral Center for the Prevention of Cardiometabolic Diseases (CIPCA) and 
      Instituto Masira, UDES, Bucaramanga, Colombia.
FAU - Toth, Peter P
AU  - Toth PP
AD  - University of Illinois College of Medicine, Peoria, Illinois, Michigan State, 
      USA.
FAU - Amaro, A Juan J
AU  - Amaro AJJ
AD  - Clinica Santa Sofia, Caracas, Venezuela.
FAU - Rodrigo, Alfonso K
AU  - Rodrigo AK
AD  - Advanced Center for Metabolic Medicine and Nutrition, Santiago de Chile, Chile.
FAU - Lanas, Fernando
AU  - Lanas F
AD  - University of La Frontera, Temuco, Chile.
FAU - Urina-Triana, Miguel
AU  - Urina-Triana M
AD  - Faculty of Health Sciences, Simon Bolivar University, Barranquilla Colombia.
FAU - Lara, Jofre
AU  - Lara J
AD  - Department of Cardiology, Hospital Solca Guayaquil, Ecuador.
FAU - Valdes, T Osiris
AU  - Valdes TO
AD  - Central Medical Center La Romana, Dominican Republic.
FAU - Gomez-Mancebo, Jose R
AU  - Gomez-Mancebo JR
AD  - Department of Cardiology, Hospital Universitario de Caracas, Universidad Central 
      de Venezuela, Caracas, Venezuela.
FAU - Bryce, Alfonso
AU  - Bryce A
AD  - CARDIOGOLF Research Unit, El Golf Clinic, Lima, Peru.
FAU - Cobos S, Leonardo
AU  - Cobos S L
AD  - Cardiology Service, Hospital El Pino, Cardiocob Research Unit, Santiago de Chile, 
      Chile.
FAU - Puente-Barragan, Adriana
AU  - Puente-Barragan A
AD  - Centro Medico Nacional 20 de Noviembre (ISSSTE), Mexico City, Mexico.
FAU - Ullauri-Solorzano, Vladimir E
AU  - Ullauri-Solorzano VE
AD  - Hospital Metropolitano, Quito, Ecuador.
FAU - Medina-Palomino, Felix A
AU  - Medina-Palomino FA
AD  - Univeridad Peruana Cayetano, Hospital Nacional Cayetano Heredia, Peru.
FAU - Lozada, Alfredo F
AU  - Lozada AF
AD  - Austral University Hospital, Buenos Aires, Argentina.
FAU - Duran, Maritza
AU  - Duran M
AD  - FISPEVEN (Foundation for Clinical Research in Public and Epidemiological Health 
      in Venezuela), Clinica El Avila, Caracas, Venezuela.
FAU - Berrospi, Percy
AU  - Berrospi P
AD  - Cardiology Service, SANNA Clinica El Golf, Lima, Peru.
FAU - Miranda, David
AU  - Miranda D
AD  - Clinica San Felipe, Lima, Peru.
FAU - Badimon, Juan J
AU  - Badimon JJ
AD  - Atherothrombosis Research Unit, Cardiovascular Institute, The Mount Sinai School 
      of Medicine, New York, USA.
FAU - Gonzalez, J Jose R
AU  - Gonzalez JJR
AD  - University Hospital Complex of Santiago de Compostela, Santiago de Compostela, 
      Galicia, Spain.
FAU - Libby, Peter
AU  - Libby P
AD  - Division of Cardiovascular Medicine, Department of Medicine, Brigham and Womens' 
      Hospital, Harvard Medical School, Boston, MA, USA.
LA  - eng
PT  - Journal Article
DEP - 20220103
PL  - Mexico
TA  - Arch Cardiol Mex
JT  - Archivos de cardiologia de Mexico
JID - 101126728
RN  - 0 (Lipids)
SB  - IM
MH  - *Atherosclerosis
MH  - *Cardiology
MH  - Consensus
MH  - Endothelium
MH  - Humans
MH  - Latin America
MH  - Lipids
MH  - United States
PMC - PMC8771033
OTO - NOTNLM
OT  - Residual risk
OT  - Cardiovascular risk
OT  - Cardiometabolic risk factors
OT  - Atherosclerotic cardiovascular disease
OT  - Inflammation
OT  - Thrombosis
COIS- On behalf of all Co-Authors, I Carlos I. Ponte-Negretti the corresponding author 
      do have the responsibility for the submission. All authors were requested to 
      disclose any actual or potential conflict of interest including any financial, 
      personal or other relationships with other people or organizations within 3 years 
      of beginning the submitted work that could inappropriately influence, or be 
      perceived to influence, their work.
EDAT- 2021/06/30 06:00
MHDA- 2022/03/11 06:00
PMCR- 2021/06/28
CRDT- 2021/06/29 20:31
PHST- 2021/06/29 20:31 [entrez]
PHST- 2021/06/30 06:00 [pubmed]
PHST- 2022/03/11 06:00 [medline]
PHST- 2021/06/28 00:00 [pmc-release]
AID - ACM-92-99 [pii]
AID - 10.24875/ACM.21000005 [doi]
PST - epublish
SO  - Arch Cardiol Mex. 2022 Jan 3;92(1):99-112. doi: 10.24875/ACM.21000005.